vs

Side-by-side financial comparison of HARROW, INC. (HROW) and WisdomTree, Inc. (WT). Click either name above to swap in a different company.

WisdomTree, Inc. is the larger business by last-quarter revenue ($159.5M vs $89.1M, roughly 1.8× HARROW, INC.). WisdomTree, Inc. runs the higher net margin — 25.5% vs 7.4%, a 18.0% gap on every dollar of revenue. On growth, WisdomTree, Inc. posted the faster year-over-year revenue change (47.5% vs 33.3%). Over the past eight quarters, HARROW, INC.'s revenue compounded faster (60.5% CAGR vs 22.1%).

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.

WisdomTree, Inc. is a global exchange-traded fund (ETF) and exchange-traded product (ETP) sponsor and asset manager with headquarters in New York. WisdomTree launched its first ETFs in June 2006, and became one of the major ETF providers in the United States. WisdomTree sponsors different ETFs that span asset classes and countries worldwide. Categories include: U.S. and International Equity, Currency, Fixed Income and Alternatives.

HROW vs WT — Head-to-Head

Bigger by revenue
WT
WT
1.8× larger
WT
$159.5M
$89.1M
HROW
Growing faster (revenue YoY)
WT
WT
+14.2% gap
WT
47.5%
33.3%
HROW
Higher net margin
WT
WT
18.0% more per $
WT
25.5%
7.4%
HROW
Faster 2-yr revenue CAGR
HROW
HROW
Annualised
HROW
60.5%
22.1%
WT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HROW
HROW
WT
WT
Revenue
$89.1M
$159.5M
Net Profit
$6.6M
$40.6M
Gross Margin
79.3%
Operating Margin
17.5%
37.2%
Net Margin
7.4%
25.5%
Revenue YoY
33.3%
47.5%
Net Profit YoY
-2.2%
76.4%
EPS (diluted)
$0.20
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HROW
HROW
WT
WT
Q1 26
$159.5M
Q4 25
$89.1M
$147.4M
Q3 25
$71.6M
$125.6M
Q2 25
$63.7M
$112.6M
Q1 25
$47.8M
$108.1M
Q4 24
$66.8M
$110.7M
Q3 24
$49.3M
$113.2M
Q2 24
$48.9M
$107.0M
Net Profit
HROW
HROW
WT
WT
Q1 26
$40.6M
Q4 25
$6.6M
$40.0M
Q3 25
$1.0M
$19.7M
Q2 25
$5.0M
$24.8M
Q1 25
$-17.8M
$24.6M
Q4 24
$6.8M
$27.3M
Q3 24
$-4.2M
$-4.5M
Q2 24
$-6.5M
$21.8M
Gross Margin
HROW
HROW
WT
WT
Q1 26
Q4 25
79.3%
Q3 25
75.3%
Q2 25
74.5%
Q1 25
67.5%
Q4 24
78.8%
Q3 24
75.6%
Q2 24
74.4%
Operating Margin
HROW
HROW
WT
WT
Q1 26
37.2%
Q4 25
17.5%
40.5%
Q3 25
20.6%
36.3%
Q2 25
17.9%
30.8%
Q1 25
-23.5%
31.6%
Q4 24
19.3%
31.7%
Q3 24
2.7%
36.0%
Q2 24
3.1%
31.3%
Net Margin
HROW
HROW
WT
WT
Q1 26
25.5%
Q4 25
7.4%
27.1%
Q3 25
1.4%
15.7%
Q2 25
7.8%
22.0%
Q1 25
-37.2%
22.8%
Q4 24
10.1%
24.7%
Q3 24
-8.6%
-4.0%
Q2 24
-13.2%
20.3%
EPS (diluted)
HROW
HROW
WT
WT
Q1 26
$0.28
Q4 25
$0.20
$0.28
Q3 25
$0.03
$0.13
Q2 25
$0.13
$0.17
Q1 25
$-0.50
$0.17
Q4 24
$0.19
$0.20
Q3 24
$-0.12
$-0.13
Q2 24
$-0.18
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HROW
HROW
WT
WT
Cash + ST InvestmentsLiquidity on hand
$72.9M
Total DebtLower is stronger
$250.0M
Stockholders' EquityBook value
$52.4M
Total Assets
$399.5M
$1.8B
Debt / EquityLower = less leverage
4.77×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HROW
HROW
WT
WT
Q1 26
Q4 25
$72.9M
Q3 25
$74.3M
Q2 25
$53.0M
Q1 25
$66.7M
Q4 24
$47.2M
Q3 24
$72.6M
Q2 24
$71.0M
$132.5M
Total Debt
HROW
HROW
WT
WT
Q1 26
Q4 25
$250.0M
Q3 25
$347.2M
Q2 25
$250.6M
Q1 25
$256.9M
Q4 24
$262.7M
Q3 24
$230.7M
Q2 24
$236.3M
Stockholders' Equity
HROW
HROW
WT
WT
Q1 26
Q4 25
$52.4M
$413.7M
Q3 25
$47.0M
$373.4M
Q2 25
$49.7M
$445.1M
Q1 25
$56.5M
$415.6M
Q4 24
$69.7M
$400.0M
Q3 24
$58.0M
$374.9M
Q2 24
$58.5M
$445.6M
Total Assets
HROW
HROW
WT
WT
Q1 26
$1.8B
Q4 25
$399.5M
$1.5B
Q3 25
$363.1M
$1.4B
Q2 25
$345.0M
$1.1B
Q1 25
$364.2M
$1.0B
Q4 24
$389.0M
$1.0B
Q3 24
$351.5M
$1.0B
Q2 24
$306.6M
$964.1M
Debt / Equity
HROW
HROW
WT
WT
Q1 26
Q4 25
4.77×
Q3 25
7.39×
Q2 25
5.05×
Q1 25
4.55×
Q4 24
3.77×
Q3 24
3.98×
Q2 24
4.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HROW
HROW
WT
WT
Operating Cash FlowLast quarter
$8.4M
$18.0M
Free Cash FlowOCF − Capex
$8.1M
FCF MarginFCF / Revenue
9.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.27×
0.44×
TTM Free Cash FlowTrailing 4 quarters
$43.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HROW
HROW
WT
WT
Q1 26
$18.0M
Q4 25
$8.4M
$147.9M
Q3 25
$16.6M
$48.1M
Q2 25
$-803.0K
$38.8M
Q1 25
$19.7M
$6.4M
Q4 24
$-17.8M
$113.5M
Q3 24
$3.0M
$47.7M
Q2 24
$-2.7M
$32.2M
Free Cash Flow
HROW
HROW
WT
WT
Q1 26
Q4 25
$8.1M
$147.7M
Q3 25
$16.4M
$48.0M
Q2 25
$-969.0K
$38.7M
Q1 25
$19.5M
$6.3M
Q4 24
$-18.3M
$113.3M
Q3 24
$2.3M
$47.7M
Q2 24
$-3.1M
$32.2M
FCF Margin
HROW
HROW
WT
WT
Q1 26
Q4 25
9.1%
100.2%
Q3 25
22.9%
38.2%
Q2 25
-1.5%
34.4%
Q1 25
40.8%
5.9%
Q4 24
-27.4%
102.4%
Q3 24
4.8%
42.1%
Q2 24
-6.3%
30.1%
Capex Intensity
HROW
HROW
WT
WT
Q1 26
Q4 25
0.4%
0.1%
Q3 25
0.3%
0.0%
Q2 25
0.3%
0.1%
Q1 25
0.4%
0.0%
Q4 24
0.8%
0.1%
Q3 24
1.2%
0.0%
Q2 24
0.7%
0.0%
Cash Conversion
HROW
HROW
WT
WT
Q1 26
0.44×
Q4 25
1.27×
3.70×
Q3 25
16.26×
2.44×
Q2 25
-0.16×
1.57×
Q1 25
0.26×
Q4 24
-2.62×
4.15×
Q3 24
Q2 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HROW
HROW

Segment breakdown not available.

WT
WT

Advisory fees$134.9M85%
Other$6.1M4%
Third-party distribution fees$5.8M4%
Management fees$5.2M3%
Sales and business development$4.2M3%
Professional fees$3.3M2%

Related Comparisons